Stem Cell Priming Medium for Anti-Inflammatory Phenotype
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell culture methods lack consistency and efficiency in producing uniform, activated stem cells for therapeutic applications, particularly in inducing anti-inflammatory phenotypes for treating systemic inflammatory diseases.
Innovation Solution
A serum-free priming medium containing a functional activator of Type I and Type II interferon pathways, along with specific pro-inflammatory cytokines, is used to induce stem cells into anti-inflammatory phenotypes with enhanced immune modulatory functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional stem cell culture methods are used, then cell expansion is achieved, but the cells lack uniform anti-inflammatory phenotype and consistent therapeutic quality
Solution Approach 1:
The patent applies preliminary action by exposing stem cells to pro-inflammatory cytokines and interferon pathway activators before therapeutic administration. This pre-treatment primes the cells to adopt an anti-inflammatory phenotype, ensuring they are pre-conditioned for their intended therapeutic function. The priming process occurs during culture expansion, so both phenotype uniformity and productivity are achieved simultaneously rather than requiring separate steps.
Solution Approach 2:
The patent employs parameter changes by modifying culture medium composition to include specific pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and interferon pathway activators at controlled concentrations. These parameter changes in the culture environment induce transcriptional reprogramming that establishes uniform anti-inflammatory phenotype across the cell population while maintaining expansion efficiency.
2Reliability
If stem cells are exposed to pro-inflammatory cytokines and interferon pathway activators, then anti-inflammatory phenotype is induced, but culture complexity increases
Solution Approach 1:
The patent applies universality by using a standardized priming medium formulation that can be applied to different stem cell sources (bone marrow, adipose, umbilical cord) to achieve consistent anti-inflammatory phenotype. The same combination of pro-inflammatory cytokines and interferon pathway activators serves multiple functions: inducing phenotype uniformity, ensuring therapeutic reliability, and maintaining cell expansion across diverse cell sources.
Solution Approach 2:
The patent uses serum-free medium components and defined growth factors as intermediaries to mediate the effect of pro-inflammatory cytokines and interferon pathway activators on stem cells. These intermediary substances create a controlled signaling environment that reliably induces anti-inflammatory phenotype without the variability introduced by serum components, thereby simplifying quality control despite the complex medium composition.
3Reliability
If stem cells are primed with specific media components, then immune modulatory function is enhanced, but production cost increases
Solution Approach 1:
The patent applies partial action by using defined, sub-physiological concentrations of pro-inflammatory cytokines and interferon pathway activators in the priming medium. Rather than using high doses that would be prohibitively expensive, optimized lower concentrations are used that still achieve reliable induction of anti-inflammatory phenotype and consistent immune modulatory function, thereby reducing medium cost while maintaining therapeutic potency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces stem cells with significantly increased anti-inflammatory gene expression and immune modulatory mediator secretion, effectively regulating immune activity and promoting tissue regeneration, as demonstrated in pre-clinical models.
Implementation Method 1
a functional activator of a Type I interferon (IFN) pathway and a Type II IFN pathway
Implementation Method 2
at least two pro-inflammatory cytokines
Data Source
AI summary
One aspect of the present disclosure can include a priming medium for creating an isolated population of stem cells having an anti-inflammatory phenotype from an unprimed population of stem cells. The priming media can include a serum-free medium, a functional activator of a Type I interferon (IFN) pathway and a Type II IFN pathway, and at least two pro-inflammatory cytokines. The functional activator and the at least two pro-inflammatory cytokines can be present in an amount sufficient to promote induction of stem cells having an anti-inflammatory phenotype. The cells having an anti-inflammatory phenotype can be marked by increased expression and/or secretion of one or more anti-inflammatory or immune modulatory mediators as compared to the unprimed population of stem cells. Other aspects of the present disclosure can include stem cells made according to the present disclosure as well as therapeutic compositions and uses of the stem cells.